Zealand Pharma Signs Licensing Agreement With Abbott Laboratories for the Further Clinical Development and Commercialization of AP214 (ZP1480) for Prevention of Acute Kidney Injury

COPENHAGEN, May 3, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, announces that a lic…
Read the full story: BioSpace.com Featured News